252 related articles for article (PubMed ID: 9467534)
1. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
[TBL] [Abstract][Full Text] [Related]
2. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
[TBL] [Abstract][Full Text] [Related]
6. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
[TBL] [Abstract][Full Text] [Related]
7. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
[TBL] [Abstract][Full Text] [Related]
8. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
9. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
[TBL] [Abstract][Full Text] [Related]
10. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans.
Clemmons DR; Smith-Banks A; Underwood LE
J Clin Endocrinol Metab; 1992 Jul; 75(1):234-8. PubMed ID: 1619015
[TBL] [Abstract][Full Text] [Related]
11. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
Schleim KD; Jacks T; Cunningham P; Feeney W; Frazier EG; Niebauer GW; Zhang D; Chen H; Smith RG; Hickey G
Endocrinology; 1999 Apr; 140(4):1552-8. PubMed ID: 10098487
[TBL] [Abstract][Full Text] [Related]
12. Effects of insulin-like growth factor I combined with growth hormone on glucocorticoid-induced whole-body protein catabolism in man.
Berneis K; Ninnis R; Girard J; Frey BM; Keller U
J Clin Endocrinol Metab; 1997 Aug; 82(8):2528-34. PubMed ID: 9253329
[TBL] [Abstract][Full Text] [Related]
13. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
Dall R; Longobardi S; Ehrnborg C; Keay N; Rosén T; Jørgensen JO; Cuneo RC; Boroujerdi MA; Cittadini A; Napoli R; Christiansen JS; Bengtsson BA; Sacca L; Baxter RC; Basset EE; Sönksen PH
J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone (GH) and insulin-like growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine.
Chang CH; Rickes EL; McGuire L; Frazier E; Chen H; Barakat K; Nargund R; Patchett A; Smith RG; Hickey GJ
Endocrinology; 1996 Nov; 137(11):4851-6. PubMed ID: 8895356
[TBL] [Abstract][Full Text] [Related]
15. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.
Hickey GJ; Jacks TM; Schleim KD; Frazier E; Chen HY; Krupa D; Feeney W; Nargund RP; Patchett AA; Smith RG
J Endocrinol; 1997 Feb; 152(2):183-92. PubMed ID: 9071975
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers.
Garcia JM; Polvino WJ
Growth Horm IGF Res; 2009 Jun; 19(3):267-73. PubMed ID: 19196529
[TBL] [Abstract][Full Text] [Related]
18. Effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone on serum IGF-binding proteins in calorically restricted adults.
Young SC; Underwood LE; Celniker A; Clemmons DR
J Clin Endocrinol Metab; 1992 Aug; 75(2):603-8. PubMed ID: 1379258
[TBL] [Abstract][Full Text] [Related]
19. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
20. L-692,429, a nonpeptide growth hormone (GH) secretagogue, reverses glucocorticoid suppression of GH secretion.
Gertz BJ; Sciberras DG; Yogendran L; Christie K; Bador K; Krupa D; Wittreich JM; James I
J Clin Endocrinol Metab; 1994 Sep; 79(3):745-9. PubMed ID: 8077355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
